NASDAQ : NERV
Minerva Neurosciences, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 2.05 USD (Oct 30, 2026, 3:16 PM EDT) · Market cap 97.88M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cost of Revenue | 12.71M | |||||
| Gross Profit | -12.71M | |||||
| Selling, General & Admin | 13.00M | 9.34M | 9.95M | 10.41M | 10.58M | 13.33M |
| Research & Development | 15.54M | 5.76M | 11.90M | 14.65M | 16.84M | |
| Operating Expenses | 28.54M | 15.10M | 21.85M | 10.41M | 25.23M | 30.17M |
| Operating Income | -28.54M | -15.10M | -21.85M | -23.12M | -25.23M | -30.17M |
| Interest Expense | -4.56M | -8.28M | -7.41M | -6.33M | ||
| Interest & Investment Income | 1.85M | 948.12K | 1.27M | 1.44M | 556.95K | 16.52K |
| Currency Exchange Gain (Loss) | -43.22K | -56.55K | -1.93K | -40.23K | -27.74K | -32.85K |
| Other Non Operating Income (Expenses) | -361.02M | -279.21M | 26.58M | |||
| EBT Excluding Unusual Items | -387.75M | -293.42M | 1.44M | -30.01M | -32.11M | -36.51M |
| Asset Writedown | -15.20M | |||||
| Pretax Income | -394.35M | -293.42M | 1.44M | -30.01M | -32.11M | -51.71M |
| Income Tax Expense | -1.80M | |||||
| Net Income | -394.35M | -293.42M | 1.44M | -30.01M | -32.11M | -49.91M |
| Net Income to Common | -394.35M | -293.42M | 1.44M | -30.01M | -32.11M | -49.91M |
| Shares Outstanding (Basic) | 27.31M | 8.46M | 7.57M | 6.51M | 5.34M | 5.34M |
| Shares Outstanding (Diluted) | 27.31M | 8.46M | 7.57M | 6.51M | 5.34M | 5.34M |
| EPS (Basic) | -14.44 | -34.67 | 0.19 | -4.61 | -6.01 | -9.35 |
| EPS (Diluted) | -14.44 | -34.67 | 0.19 | -4.61 | -6.01 | -9.35 |
| Free Cash Flow | -26.17M | -13.51M | -19.55M | -14.78M | -24.66M | -24.60M |
| Free Cash Flow Per Share | -0.96 | -1.60 | -2.58 | -2.27 | -4.62 | -4.61 |
| EBITDA | -28.53M | -15.10M | -21.84M | -23.11M | -30.15M | |
| D&A For EBITDA | 5.44K | 5.44K | 5.44K | 5.44K | 16.01K | |
| EBIT | -28.54M | -15.10M | -21.85M | -23.12M | -25.23M | -30.17M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 24.65M | 82.30M | 21.36M | 40.91M | 36.09M | 60.76M |
| Short-Term Investments | 50.62M | |||||
| Cash & Short-Term Investments | 75.27M | 82.30M | 21.36M | 40.91M | 36.09M | 60.76M |
| Other Receivables | 3.12M | |||||
| Receivables | 3.12M | |||||
| Prepaid Expenses | 4.37M | 697.68K | 806.89K | 989.87K | 848.12K | 1.35M |
| Restricted Cash | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K |
| Total Current Assets | 79.73M | 83.10M | 22.27M | 42.00M | 40.16M | 62.20M |
| Property, Plant & Equipment | 5.44K | 10.88K | 16.33K | |||
| Goodwill | 14.87M | 14.87M | 14.87M | 14.87M | 14.87M | 14.87M |
| Other Intangible Assets | 17.03K | 42.57K | 51.08K | |||
| Long-Term Deferred Charges | 487.03K | |||||
| Total Assets | 95.09M | 97.97M | 37.14M | 56.90M | 55.09M | 77.12M |
| Accounts Payable | 1.45M | 639.71K | 1.61M | 1.81M | 969.67K | 1.85M |
| Accrued Expenses | 2.51M | 1.65M | 1.23M | 1.54M | 407.91K | 965.74K |
| Total Current Liabilities | 3.96M | 2.29M | 2.84M | 3.34M | 1.38M | 2.82M |
| Long-Term Debt | 60.00M | 60.00M | 60.00M | 82.02M | 73.73M | 66.33M |
| Other Long-Term Liabilities | 232.69M | 171.46M | ||||
| Total Liabilities | 296.65M | 233.76M | 62.84M | 85.36M | 75.11M | 69.15M |
| Common Stock | 4.72K | 4.33K | 699.00 | 699.00 | 534.00 | 534.00 |
| Additional Paid-In Capital | 583.43M | 548.05M | 369.68M | 368.36M | 346.79M | 342.68M |
| Retained Earnings | -796.74M | -688.80M | -395.38M | -396.82M | -366.81M | -334.70M |
| Total Common Equity | -213.30M | -140.75M | -25.69M | -28.46M | -20.02M | 7.98M |
| Shareholders' Equity | -201.56M | -135.79M | -25.69M | -28.46M | -20.02M | 7.98M |
| Total Liabilities & Equity | 95.09M | 97.97M | 37.14M | 56.90M | 55.09M | 77.12M |
| Total Debt | 60.00M | 60.00M | 60.00M | 82.02M | 73.73M | 66.33M |
| Net Cash (Debt) | 15.27M | 22.30M | -38.64M | -41.10M | -37.64M | -5.57M |
| Net Cash Per Share | 0.56 | 2.64 | -5.10 | -6.32 | -7.05 | -1.04 |
| Filing Date Shares Outstanding | 47.75M | 43.27M | 6.99M | 6.99M | 5.34M | 5.34M |
| Total Common Shares Outstanding | 47.23M | 43.27M | 6.99M | 6.99M | 5.34M | 5.34M |
| Working Capital | 75.77M | 80.81M | 19.43M | 38.66M | 38.78M | 59.38M |
| Book Value Per Share | -4.52 | -3.25 | -3.67 | -4.07 | -3.75 | 1.49 |
| Tangible Book Value | -228.17M | -155.62M | -40.56M | -43.34M | -34.94M | -6.94M |
| Tangible Book Value Per Share | -4.83 | -3.60 | -5.80 | -6.20 | -6.54 | -1.30 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -394.35M | -293.42M | 1.44M | -30.01M | -32.11M | -49.91M |
| Depreciation & Amortization | 2.72K | 5.44K | 5.44K | 5.44K | 101.79K | |
| Other Amortization | 17.03K | 25.54K | 8.51K | |||
| Asset Writedown & Restructuring Costs | 15.20M | |||||
| Loss (Gain) From Sale of Investments | -534.47K | |||||
| Stock-Based Compensation | 11.72M | 1.33M | 1.33M | 1.97M | 4.11M | 5.22M |
| Other Operating Activities | 361.02M | 279.21M | -22.02M | 8.28M | 7.41M | 4.52M |
| Change in Accounts Payable | 423.37K | -1.06M | -197.48K | 835.65K | -883.55K | 857.60K |
| Change in Other Net Operating Assets | -4.44M | 426.67K | -123.13K | 4.10M | -3.18M | -598.27K |
| Operating Cash Flow | -26.17M | -13.51M | -19.55M | -14.78M | -24.65M | -24.60M |
| Capital Expenditures | -16.33K | |||||
| Investment in Securities | -50.13M | |||||
| Investing Cash Flow | -50.13M | -16.33K | ||||
| Issuance of Common Stock | 91.70M | 80.00M | 20.00M | |||
| Other Financing Activities | -6.00M | -5.55M | -396.29K | -5.00 | 60.00M | |
| Financing Cash Flow | 85.70M | 74.45M | 19.60M | -5.00 | 60.00M | |
| Net Cash Flow | 9.40M | 60.94M | -19.55M | 4.82M | -24.66M | 35.40M |
| Free Cash Flow | -26.17M | -13.51M | -19.55M | -14.78M | -24.66M | -24.60M |
| Free Cash Flow Per Share | -0.96 | -1.60 | -2.58 | -2.27 | -4.62 | -4.61 |
| Levered Free Cash Flow | -8.86M | -8.54M | -15.48M | -12.69M | -20.36M | -17.08M |
| Unlevered Free Cash Flow | -8.86M | -8.54M | -12.63M | -7.51M | -15.73M | -13.13M |
| Change in Working Capital | -4.02M | -632.35K | -320.60K | 4.94M | -4.06M | 259.33K |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 110.77M | 173.96M | 15.54M | 43.01M | 8.49M | 34.22M |
| Enterprise Value | 95.51M | 221.68M | 49.01M | 75.93M | 40.11M | 33.23M |
| Last Close Price | 2.32 | 4.02 | 2.22 | 6.15 | 1.59 | 6.41 |
| PE Ratio | 10.80 | |||||
| PB Ratio | -1.28 | -0.60 | -1.51 | -0.42 | 4.29 | |
| Debt / Equity Ratio | -0.30 | -0.44 | -2.33 | -2.88 | -3.68 | 8.32 |
| Net Debt / Equity Ratio | 0.08 | 0.16 | -1.50 | -1.44 | -1.88 | 0.70 |
| Net Debt / EBITDA Ratio | 0.54 | 1.48 | -1.77 | -1.78 | -0.18 | |
| Net Debt / FCF Ratio | 0.58 | 1.65 | -1.98 | -2.78 | -1.53 | -0.23 |
| Quick Ratio | 19.02 | 35.93 | 7.53 | 12.25 | 28.46 | 21.55 |
| Current Ratio | 20.14 | 36.28 | 7.85 | 12.57 | 29.15 | 22.07 |
| Return on Equity (ROE) | -164.60% | |||||
| Return on Assets (ROA) | -28.42% | -13.97% | -29.04% | -25.81% | -23.86% | -27.98% |
| Return on Capital Employed (ROCE) | -31.30% | -15.80% | -63.70% | -43.20% | -47.00% | -40.60% |
| Earnings Yield | -622.46% | -168.67% | 9.26% | -69.77% | -378.15% | -145.84% |
| FCF Yield | -23.62% | -7.77% | -125.84% | -34.38% | -290.45% | -71.89% |
| Buyback Yield / Dilution | -260.56% | -11.75% | -16.41% | -21.84% | 0.00% | -4.41% |